TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Prophase Labs ( (PRPH) ) is now available.
On September 9, 2025, ProPhase Labs held a Special Meeting of Stockholders where 63.54% of shares were voted. The stockholders approved several proposals including amendments to equity compensation plans, an increase in authorized shares, a share repurchase program, and changes to the company’s bylaws, indicating strategic adjustments to enhance operational flexibility and shareholder value.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
Spark’s Take on PRPH Stock
According to Spark, TipRanks’ AI Analyst, PRPH is a Neutral.
Prophase Labs’ overall stock score is primarily impacted by its financial challenges, including declining revenues and negative profitability. While technical indicators show some positive momentum, valuation concerns persist due to a negative P/E ratio. The earnings call and corporate events provide some optimism with potential cash recovery and strategic initiatives, but these are overshadowed by current financial instability.
To see Spark’s full report on PRPH stock, click here.
More about Prophase Labs
ProPhase Labs, Inc. operates in the healthcare industry, focusing on the development and commercialization of diagnostic tests and over-the-counter consumer healthcare products.
Average Trading Volume: 7,211,808
Technical Sentiment Signal: Sell
Current Market Cap: $18.01M
See more insights into PRPH stock on TipRanks’ Stock Analysis page.